The laboratory cannot release a single billable, reportable patient result until it holds a CLIA certificate appropriate to the testing it performs and has cleared the accreditation and licensing gauntlet that sits on top of it. This Article covers the regulatory go-live milestone — the certificates, surveys, mock inspections, deficiency-management cycles, and physical-readiness checks that convert a built-and-validated laboratory into a legally operating clinical service. It assumes instruments are already installed and validated and that the LIS and workflow are operationally ready (covered by the sibling Articles); the focus here is the accreditation and inspection sequence that gates first live testing.

Why accreditation, not just construction completion, is the real go-live gate

For most clinical service lines, the activation milestone that matters to operations is the certificate of occupancy plus internal readiness sign-off. The laboratory is different: a fully built, commissioned, staffed, and equipped lab is still legally prohibited from reporting patient results until the federal Clinical Laboratory Improvement Amendments (CLIA) framework is satisfied. CLIA — administered by the Centers for Medicare & Medicaid Services (CMS) — governs every laboratory in the United States that examines human specimens for the purpose of diagnosis, prevention, or treatment, regardless of payer or setting.

This creates a second, parallel critical path that runs alongside design and construction. A project that hits substantial completion and TCO/CO on schedule can still miss its clinical go-live date by weeks or months if the CLIA certificate, the accreditation survey, or the personnel credentialing lags. The owner, PMO, and lab leadership must therefore treat accreditation readiness as a first-class activation workstream with its own milestone schedule, owner, and dependency map — not as a back-office formality that runs itself.

The practical consequence for the construction and activation team is that the building must be survey-ready, not merely occupancy-ready, before first results. Surveyors evaluate the physical environment — biosafety containment, eyewash/safety-shower placement and flow, fume-hood and biosafety-cabinet certification, chemical and waste storage, temperature-monitored storage, signage, and life-safety conditions — as part of the laboratory's compliance, and physical deficiencies surface as citations against the lab even when they are technically a facilities issue.

The CLIA certificate ladder and how it is obtained

CLIA tiers a laboratory by the complexity of the testing it performs, and the certificate type drives everything downstream — fees, inspection regime, personnel requirements, and which accreditor (if any) applies.

A new hospital or reference laboratory performing chemistry, hematology, microbiology, blood bank, and anatomic pathology will almost always operate under a Certificate of Accreditation, because it elects a deemed accreditor (most commonly the College of American Pathologists, CAP) to perform its biennial survey in lieu of a direct CMS survey.

Obtaining the certificate follows a defined sequence that should be scheduled backward from the target go-live:

1. File CMS Form CMS-116 (CLIA application) with the state agency, declaring the testing the lab will perform by specialty and subspecialty, the estimated annual test volume, and the certificate type sought.
2. Receive the CLIA number. A registration/initial certificate is typically issued so the lab can begin operating once other conditions are met; a high-complexity lab cannot legally test patients before the CLIA number is in hand.
3. Name the CLIA-required personnel — most critically the Laboratory Director, who for high-complexity testing must meet specific qualification thresholds (board-certified pathologist, or doctoral scientist with the requisite certification and experience). The director's credentials must be on file and accepted; a lab cannot go live without an accepted director. Technical supervisors, clinical consultant, general supervisor, and testing-personnel qualifications must also be documented.
4. Stand up proficiency testing (PT) enrollment for every regulated analyte the lab will report, with an approved PT provider, before reporting patient results in those analytes.
5. Pay fees scaled to certificate type and projected test volume.

Because the director qualification and PT enrollment are gating items with their own lead times, they belong on the activation critical path months ahead of the building milestone.

CLIA, accreditation, and licensure are three distinct layers

A common planning error is to treat "getting accredited" as a single event. It is three stacked, independently failing layers:

• Federal CLIA certificate (CMS) — the legal license to test human specimens. Mandatory, nationwide, no exceptions for clinical testing.
• Accreditation by a CMS-deemed organization — when the lab elects a CoA, an approved accreditor surveys it on CMS's behalf. The major deemed laboratory accreditors are the College of American Pathologists (CAP), The Joint Commission (TJC) laboratory program, COLA, AABB (for transfusion/cellular-therapy services), and others. CAP is dominant for hospital and academic core labs; AABB is the standard for the blood bank/transfusion service and is frequently held in addition to the core-lab accreditation. The hospital's overall accreditor (TJC or DNV for the facility) is a separate question from the laboratory's accreditor — a TJC-accredited hospital may run a CAP-accredited lab.